Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879606 | 1.00 | KMT2A (0.61) | KMT2ACYP11B1CYP11B2UGT2B17DRD2 | |
| SCHEMBL1872298 | 1.00 | KMT2A (0.61) | KMT2ACYP11B1CYP11B2UGT2B17DRD2 | |
| SCHEMBL29741068 | 1.00 | KMT2A (0.61) | KMT2ACYP11B1CYP11B2UGT2B17DRD2 | |
| SCHEMBL1413268 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL2196969 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL29529595 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL5784676 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL2195961 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL31181835 | 0.89 | KMT2A (0.50) | KMT2ACYP11B1CYP11B2DRD2PGR | |
| SCHEMBL17190664 | 0.79 | KMT2A (0.42) | KMT2ADRD2S1PR1DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498611-B1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SÀRL (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9394264-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394264-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20130196966-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196966-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8357706-B2 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| EP-2498611-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | Receptos, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110178056-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-21 | — | — | US | disclosed |
| WO-2011060389-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060389-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196966-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | KMT2A 4293/4885CYP11B1 418/4885CYP11B2 739/4885 |
| US-20150299150-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | KMT2A 4293/4885CYP11B1 418/4885CYP11B2 739/4885 |
| US-20110178056-A1 | SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | KMT2A 4280/4885CYP11B1 435/4885CYP11B2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.